Centessa Pharmaceuticals (CNTA)
(Delayed Data from NSDQ)
$11.01 USD
+0.46 (4.36%)
Updated Aug 13, 2024 04:00 PM ET
After-Market: $11.01 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$11.01 USD
+0.46 (4.36%)
Updated Aug 13, 2024 04:00 PM ET
After-Market: $11.01 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth D Momentum F VGM
Zacks News
Are Medical Stocks Lagging Stryker (SYK) This Year?
by Zacks Equity Research
Here is how Stryker (SYK) and Centessa Pharmaceuticals PLC Sponsored ADR (CNTA) have performed compared to their sector so far this year.
Wall Street Analysts Believe Centessa Pharmaceuticals (CNTA) Could Rally 48.85%: Here's is How to Trade
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 48.9% in Centessa Pharmaceuticals (CNTA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Down -10.98% in 4 Weeks, Here's Why You Should You Buy the Dip in Centessa Pharmaceuticals (CNTA)
by Zacks Equity Research
Centessa Pharmaceuticals (CNTA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
The Zacks Analyst Blog Highlights Amphastar Pharmaceuticals, Journey Medical, Centessa Pharmaceuticals and Aquestive Therapeutics
by Zacks Equity Research
Amphastar Pharmaceuticals, Journey Medical, Centessa Pharmaceuticals and Aquestive Therapeutics are part of the Zacks top Analyst Blog.
What Awaits These 4 Drug Stocks That More Than Doubled in 2023?
by Ahan Chakraborty
Here are four drug, biotech stocks, AMPH, DERM, CNTA & AQST, which have more than doubled in 2023 with room for further growth in 2024.
Does Centessa Pharmaceuticals PLC Sponsored ADR (CNTA) Have the Potential to Rally 40.85% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 40.9% in Centessa Pharmaceuticals PLC Sponsored ADR (CNTA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts Predict a 35.92% Upside in Centessa Pharmaceuticals PLC Sponsored ADR (CNTA): Here's What You Should Know
by Zacks Equity Research
The consensus price target hints at a 35.9% upside potential for Centessa Pharmaceuticals PLC Sponsored ADR (CNTA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Centessa (CNTA) Surges 72% in the Past 3 Months: Here's Why
by Zacks Equity Research
Centessa (CNTA) shares rise significantly in the past three months due to the encouraging progress in the development of its lead pipeline candidate, SerpinPC, which is currently in mid-late-stage studies.
Should You Buy Centessa Pharmaceuticals (CNTA) Ahead of Earnings?
by Zacks Equity Research
Centessa Pharmaceuticals (CNTA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Cardinal Health (CAH) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
Cardinal Health's (CAH) fiscal fourth-quarter results are likely to reflect solid performance in the Pharmaceutical segment. However, inflation and supply chain constraints are likely to have continued.
Doximity (DOCS) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Doximity's (DOCS) fiscal first-quarter results are likely to reflect continued strength in its fax, e-signature and telehealth products.
BD (BDX) Gears Up for Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Continued strength in BD's (BDX) Interventional segment is expected to have driven up Q3 sales.
Abiomed (ABMD) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Continued strength in Abiomed's (ABMD) Impella product line is expected to have driven Q1 sales.
McKesson (MCK) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
McKesson's (MCK) fiscal first-quarter results are likely to reflect the solid show by the U.S. Pharmaceutical and Specialty Solutions segment.
What's in the Offing for QuidelOrtho (QDEL) in Q2 Earnings?
by Zacks Equity Research
QuidelOrtho's (QDEL) second-quarter results are likely to reflect strength across both its COVID and non-COVID businesses.
AMN Healthcare (AMN) to Post Q2 Earnings: What's in the Cards?
by Zacks Equity Research
AMN Healthcare's (AMN) second-quarter results are likely to reflect solid demand across all its segments.
NextGen Healthcare (NXGN) Beats on Q1 Earnings, Cuts FY23 View
by Zacks Equity Research
NextGen Healthcare's (NXGN) first-quarter fiscal 2023 results reflect strength in its Recurring revenues.
Wall Street Analysts Predict a 128% Upside in Centessa Pharmaceuticals PLC Sponsored ADR (CNTA): Here's What You Should Know
by Zacks Equity Research
The mean of analysts' price targets for Centessa Pharmaceuticals PLC Sponsored ADR (CNTA) points to a 127.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Centessa Pharmaceuticals (CNTA) Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Centessa Pharmaceuticals (CNTA) has been struggling lately, but the selling pressure may be coming to an end soon.